Swiss National Bank Increases Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

Swiss National Bank lifted its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 178,600 shares of the company’s stock after acquiring an additional 1,800 shares during the quarter. Swiss National Bank’s holdings in Myriad Genetics were worth $2,449,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Point72 Hong Kong Ltd purchased a new stake in Myriad Genetics in the third quarter valued at $32,000. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after purchasing an additional 1,471 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Myriad Genetics in the 3rd quarter valued at about $153,000. KBC Group NV grew its stake in Myriad Genetics by 132.8% during the 4th quarter. KBC Group NV now owns 5,845 shares of the company’s stock worth $80,000 after buying an additional 3,334 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new position in Myriad Genetics during the third quarter worth approximately $212,000. Institutional investors and hedge funds own 99.02% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MYGN. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Tuesday. UBS Group lowered their price objective on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 25th. Leerink Partners cut shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $30.00 to $21.00 in a report on Monday, December 9th. Craig Hallum assumed coverage on Myriad Genetics in a report on Wednesday, February 12th. They set a “buy” rating and a $29.00 price target on the stock. Finally, Raymond James reaffirmed an “outperform” rating and set a $19.00 price objective (down from $27.00) on shares of Myriad Genetics in a research note on Tuesday, February 25th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and an average price target of $21.89.

Myriad Genetics Price Performance

Shares of NASDAQ MYGN opened at $9.22 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. Myriad Genetics, Inc. has a one year low of $9.18 and a one year high of $29.30. The firm has a market capitalization of $841.87 million, a P/E ratio of -7.09 and a beta of 1.79. The company’s fifty day moving average is $11.83 and its two-hundred day moving average is $16.70.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The company had revenue of $210.60 million for the quarter, compared to analysts’ expectations of $210.35 million. During the same period in the prior year, the firm posted ($0.12) EPS. Analysts forecast that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.